ArticleNPJ vaccines2019
Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody.
Article in NPJ vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Global seroprevalence of Zika virus in asymptomatic individuals: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Trial
- Evaluation of candidate reference materials for the harmonization of Lassa fever serology.Emerging microbes & infections · 2026Article
- Article
- Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data.Epidemics · 2024Review
- WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.NPJ vaccines · 2024Article
- Serological Evidence of Zika Virus Infections in Sudan.Viruses · 2024Article
- A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.The Journal of infectious diseases · 2023Review
- Availability and use of Standards in vaccine development.NPJ vaccines · 2023Review
- Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody.Viruses · 2022Review
- Article
- Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications.Frontiers in microbiology · 2022Article
- Application of SARS-CoV-2 Serology to Address Public Health Priorities.Frontiers in public health · 2021Article
- Article
- Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications.PLoS neglected tropical diseases · 2020Article
- Zika vaccine pre-clinical and clinical data review with perspectives on the future development.Human vaccines & immunotherapeutics · 2020Article
- Passive immunisation of convalescent human anti-Zika plasma protects against challenge with New World Zika virus in cynomolgus macaques.NPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 15 institutions in 6 countries.
Funding
Abstract
During outbreaks of emerging viruses, such as the Zika outbreak in 2015-2016, speed and accuracy in detection of infection are critical factors to control the spread of the disease; often serological and diagnostic methods for emerging viruses are not well developed and validated. Thus, vaccines and treatments are difficult to evaluate due to the lack of comparable methods. In this study, we show how the 1st WHO International Standard for anti-Zika antibody was able to harmonize the neutralization titres of a panel of serological Zika-positive samples from laboratories worldwide. Expression of the titres in International Unit per millilitre reduced the inter-laboratory variance, allowing for greater comparability between laboratories. We advocate the use of the International Standard for anti-Zika virus antibodies for the calibration of neutralization assays to create a common language, which will permit a clear evaluation of the results of different clinical trials and expedite the vaccine/treatment development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.